Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hematologic Neoplasms × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Cholangiocarcinoma 4 Urinary Bladder Neoplasms 3 Acrocephalosyndactylia 3 Stomach Neoplasms 2 Glioblastoma 2 Uterine Cervical Neoplasms 1 Upper Tract Urothelial Carcinomas 1 Tumor With Alterations of the FGF-R 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Rectal Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

Cyclophosphamide 77 fludarabine 69 fludarabine phosphate 41 Tacrolimus 39 Whole-Body Irradiation 38 Mycophenolic Acid 34 Busulfan 30 Melphalan 28 Methotrexate 21 Antilymphocyte Serum 21 thymoglobulin 20 Standard of Care 20 Thiotepa 19 Sirolimus 19 Rituximab 19 Stem Cell Transplantation 17 Azacitidine 17 venetoclax 16 Practice Guidelines as Topic 16 Granulocyte Colony-Stimulating Factor 16 Bortezomib 15 Cytarabine 14 Blood Specimen Collection 14 Filgrastim 13 Surveys and Questionnaires 12 Specimen Handling 12 Mesna 12 Nivolumab 11 Peripheral Blood Stem Cell Transplantation 9 Interviews as Topic 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02160041 2019-06-18

CBGJ398XUS04

Novartis

Phase 2 Terminated

84 enrolled 15 charts

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡